Relapse risk is significantly lower with immunosuppressive treatment after the first event, highlighting treatment importance.
The MOG-AR score did not accurately predict a relapsing disease course in the observed population.
Analysis of clinical outcomes reveals a crucial association between treatment types and relapse occurrences.
Findings suggest the need for alternative predictive models in assessing disease progression after initial events.
Abstract
MOG-AR score failed to accurately predict a relapsing disease course. Only immunosuppressive treatment after the first event was significantly associated with a lower relapse risk.